Maximus raises FY2026 EPS outlook and refreshes $400 million buyback
Maximus reported fiscal second-quarter 2026 revenue of $1.31 billion, down from $1.36 billion a year earlier, while diluted EPS rose to $1.80 from $1.69. The company raised its fiscal 2026 adjusted diluted EPS guidance by $0.20 to a range of $8.25 to $8.55 and refreshed its repurchase authorization for up to $400 million, which becomes effective May 11, 2026.
Key points
- Q2 revenue was $1.31 billion versus $1.36 billion a year earlier; the prior year benefited from natural disaster support and temporary clinical volume surges.
- Diluted EPS was $1.80 versus $1.69; adjusted diluted EPS was $2.07 versus $2.01.
- Fiscal 2026 adjusted diluted EPS guidance rose $0.20 to $8.25 to $8.55; revenue guidance of $5.2 billion to $5.35 billion was maintained.
- The board refreshed the repurchase program for up to $400 million; the company bought $111 million of stock in the quarter and another $39.9 million through May 1, 2026.
The filing
Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 07, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.